Paper1968449
The effect of salazosulfapyridine on the in vitro antibody production in murine spleen cells.
Fujiwara M and 3 others. Immunopharmacology, 1990. Cited by 16 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The effect of salazosulfapyridine on the in vitro antibody production in murine spleen cells. Papers, record 1968449. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1968449
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The effect of salazosulfapyridine on the in vitro antibody production in murine spleen cells.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibody Formation | Major topic |
| Immunosuppressive Agents | Major topic |
| Spleen | Major topic |
| Sulfasalazine | Major topic |
| Animals | |
| Erythrocytes | |
| In Vitro Techniques | |
| Interleukin-2 | |
| Kinetics | |
| Mice | |
| Mice, Inbred BALB C | |
| Mice, Inbred DBA | |
| Sheep | |
| T-Lymphocytes |
Source PubMed
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 16 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 31810227 | Switching between Three Types of Mesalazine Formulation and Sulfasalazine in Patients with Active Ulcerative Colitis Who Have Already Received High-Dose Treatment with These Agents. | J Clin Med | 2019 | https://conductscience.org/library/papers/31810227 | PubMed |
| 24723200 | Pediatric ulcerative colitis: a practical guide to management. | Paediatr Drugs | 2014 | https://conductscience.org/library/papers/24723200 | PubMed |
| 16984937 | Sulphasalazine inhibits human antigen-specific immune responses in vivo. | Ann Rheum Dis | 2007 | https://conductscience.org/library/papers/16984937 | PubMed |
| 8097101 | Comparison of the effect of oral sulphasalazine, sulphapyridine and 5-amino-salicylic acid on the in vivo antibody response to oral and systemic antigen. | Br J Clin Pharmacol | 1993 | https://conductscience.org/library/papers/8097101 | PubMed |
| 7843946 | Crohn's disease and multiple sclerosis: a single case report. | Ital J Neurol Sci | 1994 | https://conductscience.org/library/papers/7843946 | PubMed |
| 1350243 | Sulfasalazine. Multiplicity of action. | Dig Dis Sci | 1992 | https://conductscience.org/library/papers/1350243 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1968449
GET https://conductscience.org/api/papers/v1/1968449/authors